# Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Study · id `cardio:ct-nct01452139` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01452139](<https://clinicaltrials.gov/study/NCT01452139>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01452139

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT01452139. Randomized; single masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT01452139, source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01452139, source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01452139, source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)
- Completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01452139, source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT01452139, source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01452139-2013-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
- Acronym: RAPID STEMI
- Condition: STEMI
- Intervention (Genetic): Point-of-Care Genetic Testing
- Intervention (Drug): Prasugrel
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER
- Collaborator: Spartan Bioscience Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)
- Registry lists this organization as a collaborator: Spartan Bioscience Inc. (`cardio:org-spartan-bioscience-inc`)

## Provenance

Content hash: 013bd568bc2f023ed06e5b2739d6291206a1b741a1fa93b218e3bb5978f16cd0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
